IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

IDEXX Laboratories, Inc.NASDAQ: IDXX

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income grows in line with its trailing trend

Q3 FY2026 operating income of $402.35M rose 13.4% year over year, behind the +15.3% change in trailing-twelve-month operating income. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.

Context

  • Operating income amounted to 31.6% of revenue in FY2025, up 2.7 pp from a year earlier.
  • Operating income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 11 analysts of $1.52B (+11.9%) for the fiscal year ending Dec 2026, a slowdown from the +20.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$402.35M-5.5% QoQ
Last fiscal yearDec 2025
$1.36B+20.5% YoY
LTMSep 2026
$1.51B+15.3% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.4%+6.9%-6.5 pp
1 year+20.5%+11.9%-8.6 pp
3-year CAGR+14.8%+13.1%-1.8 pp
5-year CAGR+13.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
1.36B USD
Year-over-year change
+20.5%
4-year CAGR
+9.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 operating income of $1.51B is the 3rd highest of the 5 companies compared; the peer median is $2.02B.
  • Its year-over-year change of +15.3% is the 2nd highest of 5, against a peer median of -24.2%.
  • Operating income amounts to 32.3% of revenue for IDXX, versus a peer median of 13.3%.
IDXX Competitors Peer median
Operating Income for IDXX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$11.06B -48.3%+8.7%16.7%
ZTSZoetis Inc.LTM Jun 2026$3.52B +0.0%+7.1%37.0%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$1.51B +15.3%+14.8%32.3%
ELANElanco Animal Health IncorporatedLTM Sep 2026$516M +114.1%-13.1%10.0%
NEOGNeogen CorporationLTM Aug 2026-$7.38M -2443.8%—0.8%
Peer median (excluding IDXX) $2.02B-24.2%+7.1%13.3%

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.22B3.37B3.66B3.9B4.3B
Cost of Revenue1.33B1.36B1.47B1.52B1.64B
Gross Profit1.89B2B2.19B2.38B2.66B
Gross Margin58.8%59.5%59.8%61.0%61.8%
Research & Development161.01M254.82M190.95M219.79M251.21M
Selling, General & Admin796.4M850.75M901.89M1.03B1.05B
Operating Expenses957.4M1.11B1.09B1.25B1.3B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
EBITDA1.04B1.01B1.22B1.28B1.51B
EBITDA Margin32.3%30.1%33.3%32.7%35.0%
Operating Income932.03M898.77M1.1B1.13B1.36B
Operating Margin29.0%26.7%30.0%29.0%31.6%
Interest Income434K1.07M5.63M12.7M2.42M
Interest Expense29.81M39.86M41.58M31.21M38.27M
Other Income / Expenses(29.37M)(38.79M)(35.95M)(18.51M)(35.84M)
Income Before Tax902.65M859.97M1.06B1.11B1.32B
Pre-Tax Margin28.1%25.5%29.0%28.5%30.8%
Income Tax Expense157.81M180.88M216.13M221.96M264.73M
Net Income744.85M679.09M845.04M887.87M1.06B
Net Margin23.2%20.2%23.1%22.8%24.6%
EPS (Basic)8.748.1210.1710.7713.17
EPS (Diluted)8.608.0310.0610.6713.08
Weighted Avg Shares85.2M83.62M83.07M82.47M80.1M
Weighted Avg Shares (Diluted)86.57M84.6M83.98M83.25M80.68M

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.